Senseonics Moves Forward with Eversense CGM Commercialization
In an exciting development for the diabetes management sector, Senseonics Holdings, Inc. (NYSE: SENS) recently announced a strategic partnership through a Memorandum of Understanding. This collaboration paves the way for Senseonics to take over the commercialization and distribution of the Eversense 365 continuous glucose monitoring (CGM) system from Ascensia Diabetes Care.
Transition of Responsibilities
Since 2020, Ascensia has been the exclusive distributor for Eversense products. However, following the agreement, Senseonics will assume all responsibilities related to sales and marketing for the Eversense 365 beginning January 1, 2026. Until then, Ascensia will provide transitional support to facilitate a smooth transition while Senseonics leverages this opportunity to establish itself solidly in the marketplace.
New Leadership for Commercial Growth
Another significant component of this transition is the appointment of Brian Hansen as the new Chief Commercial Officer of Senseonics effective January 1, 2026. Hansen's expertise in the diabetes care industry, particularly from his previous role at Tandem Diabetes Care and as President of CGM at Ascensia, positions him to lead Senseonics effectively during this major transition.
Strategic Investment for Eversense Growth
As the demand for innovative diabetes management solutions, like the Eversense system, continues to rise, this internalization of the commercialization efforts is crucial. The leadership at Senseonics believes that having dedicated control over commercialization efforts will lead to better responsiveness to market demands, allowing for a more tailored product offering.
The Evolution of the Eversense Product
With Eversense recognized as the pioneer of long-term continuously monitoring systems, the focus now shifts to holistic brand growth. Senseonics anticipates that by directly managing its commercial channels, it can enhance patient outreach and improve overall product availability. This strategy is expected to bolster revenue and profit margins by minimizing the need for shared profits with Ascensia.
Financial Insights and Outlook
In connection with this transition, Senseonics has expanded its non-dilutive debt facility with Hercules Capital to $100 million. This funding is aimed at bolstering the commercial organization as they adapt to new operational realities. As they implement these changes, Senseonics is projecting gross margins to improve significantly, forecasting a rise to 50% in 2026 and more than 70% at scale.
Looking Ahead: Revenue Projections
For the full year ahead, Senseonics estimates that the global net revenue for 2025 could range between $34 million and $38 million, as they focus on enhancing their patient base and increasing penetration in a competitive market. This growth is expected to be driven by the rollout of Eversense 365 and could see a significant uptick in the latter half of the year.
Investor Relations and Future Plans
To keep stakeholders informed of these developments, Senseonics is hosting a conference call to discuss these transitions and financial outlook on September 4, 2025. This event will provide investors with the opportunity to gain insights directly from the company’s leadership regarding the future of Eversense and its wider strategy in the diabetes management arena.
About Senseonics and Eversense
Senseonics Holdings, Inc. is revolutionizing diabetes management with its continuous glucose monitoring solutions. The Eversense® 365 is notable for its long-term monitoring capabilities, providing users with essential glucose data directly to their smartphones. These innovative systems support individuals with diabetes, enabling them to make informed decisions regarding their health.
Conclusion: A New Chapter for Senseonics
This transition marks an exciting new chapter in the journey of Eversense and Senseonics as a whole. By bringing the commercialization efforts in-house, Senseonics aims to innovate further and expand the reach of its life-changing diabetes management solutions.
Frequently Asked Questions
What is the significance of the Memorandum of Understanding?
The Memorandum of Understanding allows Senseonics to take over the commercialization and distribution of Eversense 365, enhancing operational efficiency and market responsiveness.
Who will lead commercial efforts at Senseonics?
Brian Hansen will be stepping in as Chief Commercial Officer starting January 1, 2026, bringing valuable experience to the role.
What financial support has Senseonics secured?
Senseonics has expanded its non-dilutive debt facility with Hercules Capital to $100 million to support its commercial organization.
When is the expected revenue growth for Senseonics?
Senseonics estimates a global net revenue of approximately $34 million to $38 million for the full year of 2025, with growth expected primarily in the latter half of the year.
How does Eversense differentiate itself in the market?
Eversense is recognized as the first implantable CGM system that provides continuous glucose monitoring for an entire year, setting it apart in the diabetes care market.
